US 11,903,952 B2
Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection
Kurt Q. Lu, Chicago, IL (US); Livia A. Veress, Denver, CO (US); Kevin D. Cooper, Moreland Hills, OH (US); and Amisha Wallia, Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US); Case Western Reserve University, Cleveland, OH (US); and The Regents of the University of Colorado, Denver, CO (US)
Filed by NORTHWESTERN UNIVERSITY, Evanston, IL (US); Case Western Reserve University, Cleveland, OH (US); and The Regents of the University of Colorado, Denver, CO (US)
Filed on May 26, 2021, as Appl. No. 17/303,330.
Claims priority of provisional application 63/030,786, filed on May 27, 2020.
Prior Publication US 2021/0369741 A1, Dec. 2, 2021
Int. Cl. A61K 31/593 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); A61P 11/00 (2006.01); A61K 31/585 (2006.01)
CPC A61K 31/593 (2013.01) [A61K 31/585 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); A61P 31/14 (2018.01)] 12 Claims
 
1. A method for treating an injury in the lungs of a subject in need thereof, the method comprising: administering, as part of a regimen, an effective amount of a composition comprising vitamin D3, wherein the regimen comprises orally administering an initial dose of the composition followed by orally administering at least three additional doses of the composition, wherein a first dose of the at least three additional doses is administered five to seven days from the initial dose, and wherein the remaining doses of the at least three additional doses is administered five to seven days apart from one another, and wherein (i) the initial dose, (ii) the at least three additional doses, or (iii) both (i) and (ii) comprise about 100,000 IU to about 500,000 IU of vitamin D3.